���析表征与稳定性管理 — Background and Details

By Editorial Desk · published 2026-01-22 · last reviewed 2026-03-06 · Blog

deamidation comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Updated 2026-03-06. Numbers and descriptions here follow the published literature rather than marketing material.

分析表征与稳定性管理

稳定性研究一般关注脱酰胺、氧化与聚集三类降解路径。脱酰胺多发生在天冬酰胺残基上，氧化常涉及甲硫氨酸与色氨酸，聚集则与浓度、温度以及容器界面接触有关。强制降解实验用于识别分子中较敏感的位点。这些结果会直接影响储存条件的设定与有效期的判断。

冻干粉通常在低温环境下保存，复溶之后需要按指定条件在较短时间内使用。反复冻融和剧烈振荡可能促进聚集，低吸附容器则能减少多肽在管壁上的损失。批号、日期与处理条件的完整记录，是后续复核与问题追溯的基础。

供应环节涉及来源核实与文件审核两类工作。分析证书、批次记录以及第三方检测报告构成常见的可追溯材料。来源不清的样品很难确认身份与纯度，因此核实步骤在实际操作中具有明确意义。缺少方法细节的报告通常无法复核。

Analytical Methods, Stability, and Storage

Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.

Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.

Retatrutide at a glance

Molecular Identity and Receptor Targets

Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.

Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.

Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.

Related pages on this site

• Automated casebook
• Modular index
• Regional notes
• Durable summary
• Structured digest
• Quality briefing
• Gradual trends
• Connected toolkit

Triple Receptor Agonist Background

Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.

Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.

瑞他鲁肽开发背景

与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。

瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。

开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。

Further detail

After terminating their exclusive distribution agreement with PepsiCo, Bang alleged that PepsiCo was misrepresenting itself as the exclusive distributor of their products, and threatened lawsuits against suppliers and distributors who did not purchase Bang products directly from them. An emergency arbitrator ruled in December 2020 that Pepsi remains the exclusive distributor of Bang. Bang and PepsiCo mutually transitioned from their exclusive distribution agreement in June 2022, with then-CEO Jack Owoc claiming that "all disputes with PepsiCo have been fully settled and resolved".

== Description == The cap is white, may have fine scales, and is 3 to 12 centimetres (1+1⁄4 to 4+3⁄4 inches) in diameter; it is first hemispherical in shape before flattening out with maturity. The gills are initially pink, then red-brown and finally a dark brown, as is the spore print. The stipe is 3 to 10 cm (1+1⁄4 to 4 in) tall, 1–2 cm wide, predominantly white and bears a single thin ring. The taste is mild. The white flesh bruises a dingy reddish brown, as opposed to yellow in the poisonous Agaricus xanthodermus and similar species. The thick-walled, dark brown, elliptical spores measure 5.5–8 μm by 4–5 μm. Cheilocystidia are absent.

Similar to water, graphite oxide easily incorporates other polar solvents, e.g. alcohols. However, intercalation of polar solvents occurs significantly different in Brodie and Hummers graphite oxides. Brodie graphite oxide is intercalated at ambient conditions by one monolayer of alcohols and several other solvents (e.g. dimethylformamide and acetone) when liquid solvent is available in excess. Separation of graphite oxide layers is proportional to the size of alcohol molecule. Cooling of Brodie graphite oxide immersed in excess of liquid methanol, ethanol, acetone and dimethylformamide results in step-like insertion of an additional solvent monolayer and lattice expansion. The phase transition detected by X-ray diffraction and differential scanning calorimetry (DSC) is reversible; de-insertion of solvent monolayer is observed when sample is heated back from low temperatures. An additional methanol and ethanol monolayer is reversibly inserted into the structure of Brodie graphite oxide under high pressure conditions. Hummers graphite oxide is intercalated with two methanol or ethanol monolayers at ambient temperature. The interlayer distance of Hummers graphite oxide in an excess of liquid alcohols increases gradually upon temperature decrease, reaching 19.4 and 20.6 Å at 140 K for methanol and ethanol, respectively. The gradual expansion of the Hummers graphite oxide lattice upon cooling corresponds to insertion of at least two additional solvent monolayers.

An example of an RNA aptamer therapy includes Pegaptanib (aka Macugen ® ), the only FDA-approved RNA aptamer treatment. Originally approved in 2004 to treat age-related macular degeneration, Pegaptanib is a 28 nucleotide RNA aptamer that acts as a VEGF antagonist. However, it is not as effective as antibody-based treatments such as bevacizumab and ranibizumab. Another example of an RNA aptamer therapeutic is NOX-A12, a 45 nucleotide RNA aptamer that is in clinical trials for chronic lymphocytic leukemia, pancreatic cancer, as well as other cancers. NOX-A12 acts as antagonist for CXCL12/SDF-1, a chemokine involved in tumor growth.

Sources: en.wikipedia.org

Supporting material

March 30: Law modifying the law of November 2, 1892, on labor by children, underage girls, and women in industrial establishments: the maximum daily working hours for minors under 18 and for women is reduced to 10 hours. December 1: Law allowing women with a university degree (license) to take the oath as lawyers and practice the profession. December 29: Law defining working conditions for women employed in shops, stores, and related premises. March 31, 1902: Decree creating Agricultural Chambers in Algeria: in elections to these chambers, French women who retain their civil rights (i.e., single, divorced or legally separated, or widowed) may vote (but are not eligible to be elected). 1903

===== Daniela Carneiro ===== In the same month Minister of Tourism Daniela Carneiro came under scrutiny for her association with individuals believed to command militias in Rio de Janeiro. Carneiro, a member of the Brazil Union party, had been included by the Lula government in the Ministry of Tourism in order to increase its alliance with parties of different political positions. According to a report by Veja, Daniela, the most voted federal deputy in Rio de Janeiro in 2022, was introduced to Lula by Washington Quaquá, coordinator of Lula's campaign in Rio, and was also chosen for other characteristics considered important for the PT: being a woman and evangelical. After the appointment of Daniela, previously known as Daniela do Waguinho, press outlets began publishing a series of reports showing involvement of Carneiro's political group with militias in the Baixada Fluminense, which had also previously shown involvement and links with other politicians from right-wing parties. On 3 January, g1 published a 2018 photo of Daniela alongside Juracy Alves Prudêncio, better known as Jura, a former military police sergeant identified as the leader of a militia responsible for killings in the Baixada Fluminense. Juracy appears in videos working as a campaign worker for her. He was sentenced to 26 years in prison for murder, moved to the semi-open prison regime in 2017, and went to work at the city hall of Belford Roxo, where the mayor was Wagner dos Santos Carneiro, known as Waguinho, Daniela's husband.

== Pharmacodynamics == Emedastine is significantly selective to H1 histamine receptors (Ki = 1.3 nM), whereas its affinities for other histamine receptors were low (H2: Ki = 49067 nM and H3: Ki = 12430 nM) ub in vitro study. Topical ocular administration of emedastine inhibits histamine-stimulated vascular permeability in the conjunctiva as a concentration-dependent manner in in vitro study.

The Society holds an annual conference in late May or early June as well as topical conferences (at Asilomar State Beach in California and Sanibel Island, Florida) and a fall workshop, which is also focused on a single topic. Conferences on Mass Spectrometry and Allied Topics have been held yearly since 1953. International Mass Spectrometry Foundation List of female mass spectrometrists ASMS website

16O + γ → 15O + n 14N + γ → 13N + n 15O decays to 15N, emitting a positron. The positron quickly annihilates with an electron, producing two gamma rays of about 511 keV. After a lightning bolt, this gamma radiation dies down with half-life of 2 minutes, but these low-energy gamma rays go on average only about 90 metres through the air. Together with rays produced from positrons from nitrogen-13 they may only be detected for a minute or so as the "cloud" of 15O and 13N floats by, carried by the wind.

Sources: en.wikipedia.org

Supporting material

=== Other therapeutic uses === The 131I isotope is also used as a radioactive label for certain radiopharmaceuticals that can be used for therapy, e.g. 131I-metaiodobenzylguanidine (131I-MIBG) for imaging and treating pheochromocytoma and neuroblastoma. In all of these therapeutic uses, 131I destroys tissue by short-range beta radiation. About 90% of its radiation damage to tissue is via beta radiation, and the rest occurs via its gamma radiation (at a longer distance from the radioisotope). It can be seen in diagnostic scans after its use as therapy, because 131I is also a gamma-emitter.

The minister of agriculture, food sovereignty and forests is the head of the Republic of Italy's Ministry of Agriculture, Food Sovereignty and Forests. The ministry had been abolished by legislative referendum in 1993, during a period of great upheaval and financial sacrifices, but it was reconstituted in the same year until it assumed the current name in 2006. The current minister of the is Francesco Lollobrigida, of the Brothers of Italy party, who he is serving since 22 October 2022, in the government of Giorgia Meloni.

Embryonic mitochondrial transplant and protofection have been proposed as a possible treatment for inherited mitochondrial disease, and allotopic expression of mitochondrial proteins as a radical treatment for mtDNA mutation load. In June 2018 Australian Senate's Senate Community Affairs References Committee recommended a move towards legalising MRT. Research and clinical applications of MRT were overseen by laws made by federal and state governments. State laws were, for the most part, consistent with federal law. In all states, legislation prohibited the use of MRT techniques in the clinic, and except for Western Australia, research on a limited range of MRT was permissible up to day 14 of embryo development, subject to a license being granted. In 2010, the Hon. Mark Butler MP, then Federal Minister for Mental Health and Ageing, had appointed an independent committee to review the two relevant acts: the Prohibition of Human Cloning for Reproduction Act 2002 and the Research Involving Human Embryos Act 2002. The committee's report, released in July 2011, recommended the existing legislation remain unchanged Currently, human clinical trials are underway at GenSight Biologics (ClinicalTrials.gov # NCT02064569) and the University of Miami (ClinicalTrials.gov # NCT02161380) to examine the safety and efficacy of mitochondrial gene therapy in Leber's hereditary optic neuropathy.

=== DNA damage and cellular stress === CK1δ can be also activated by genotoxic stress and DNA damage in a p53-dependent manner, and phosphorylate key regulatory proteins in response to these processes. CK1δ phosphorylates human p53 on Ser-6, Ser-9, and Ser-20. Moreover, CK1δ phosphorylates p53 on Thr-18, once p53 is already phospho-primed, permitting a lower p53-Mdm2 binding and higher p53 activity. Under normal conditions, CK1δ can phosphorylate Mdm2 on Ser-240, Ser-242, Ser-246, and Ser-383, permitting higher p53-Mdm2 stability and further p53 degradation. On the contrary, after DNA damage, ATM phosphorylates CK1δ, which can subsequently phosphorylate Mdm2 inducing its proteasomal degradation. Under hypoxia, CK1δ is involved in reducing cell proliferation by interfering with HIF-1α/ARNT complex formation. Additionally, the activity of topoisomerase II α (TOPOII-α), one of the main regulators of DNA replication, results increased after its CK1δ-mediated phosphorylation on Ser-1106. Under stress conditions, CK1δ can interfere with DNA replication. In fact, CK1δ phosphorylates a main regulator of DNA methylation, the ubiquitin-like containing PHD and RING finger domains 1 protein (UHRF1), on Ser-108, increasing its proteasomal degradation.

== Medical uses == Lurasidone is used to treat schizophrenia and bipolar disorder. In bipolar disorder, it has been studied both as a monotherapy and adjunctive treatment to lithium or valproate. The European Medicines Agency approved lurasidone for the treatment of schizophrenia for people aged 13 years and older. Its use in Europe for bipolar disorder is considered off-label. In the United States, it is used to treat schizophrenia for people aged 13 years and older. In July 2013, lurasidone received approval for bipolar I depression. This includes depressive episodes of bipolar disorder age 10 and over as a monotherapy, and in conjunction with lithium or valproate in adults. In June 2020, lurasidone was approved in Japan, eight years after its first approval in the United States. In Japan it is approved for bipolar depression and schizophrenia. Lurasidone is not approved by the Food and Drug Administration (FDA) for the treatment of behavior disorders in older adults with dementia. Few available atypical antipsychotics are known to possess antidepressant efficacy in bipolar disorder (with the notable exceptions being cariprazine, quetiapine, olanzapine and possibly asenapine) as a monotherapy. The majority of atypical antipsychotics are known to possess significant antimanic activity, however lurasidone is unusual as it was never studied for acute mania.

Sources: en.wikipedia.org

Frequently asked questions